Open AccessEffect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
Author(s) -
Nanette Santoro,
Arthur Waldbaum,
Samuel Lederman,
Robin Kroll,
Graeme L. Fraser,
Christopher Lademacher,
Laurence Skillern,
James Young,
Steven Ramael
Publication year - 2020
Publication title -
menopause
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.086
H-Index - 103
eISSN - 1530-0374
pISSN - 1072-3714
DOI - 10.1097/gme.0000000000001621
Subject(s) - medicine , placebo , hot flash , vasomotor , climacteric , menopause , quality of life (healthcare) , dose ranging study , randomized controlled trial , double blind , breast cancer , nursing , pathology , cancer , alternative medicine
In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs).